In:
Infectious Diseases in Obstetrics and Gynecology, Wiley, Vol. 2011 ( 2011), p. 1-11
Abstract:
Objective . To evaluate if new imiquimod formulations using a shorter treatment duration are safe and efficacious to treat anogenital warts. Methods . In two studies 534 women ≥12 years of age (mean 33.4) with 2–30 warts (mean 7.9) and total wart area ≥ 10 mm 2 (mean 166.3) were randomized (1 : 2 : 2) to placebo (106), imiquimod 2.5% (212) or 3.75% (216) creams applied once daily until complete clearance or a maximum of 8 weeks. Results . For placebo, imiquimod 2.5% and 3.75%, respectively, complete clearance of all warts was achieved in 14.2%, 28.3%, and 36.6% of women (intent-to-treat, P = 0.008 imiquimod 2.5%, and P 〈 0.001 3.75% versus placebo). Mean changes in wart counts were −10.7%, −50.9%, and −63.5% (per-protocol, P 〈 0.001 each active versus placebo) and safety-related discontinuation rates 0.9%, 1.4%, and 2.3%. Conclusions . Imiquimod 3.75% applied daily for up to 8 weeks was well tolerated and superior to placebo in treating women with external anogenital warts.
Type of Medium:
Online Resource
ISSN:
1064-7449
,
1098-0997
Language:
English
Publisher:
Wiley
Publication Date:
2011
detail.hit.zdb_id:
2001451-X
detail.hit.zdb_id:
1176776-5
Permalink